Back to Search Start Over

Fibroblast Activation Protein Inhibitor Theranostics: Preclinical Combination Treatment.

Authors :
Lückerath K
Trajkovic-Arsic M
Mona CE
Source :
PET clinics [PET Clin] 2023 Jul; Vol. 18 (3), pp. 409-418. Date of Electronic Publication: 2023 Mar 27.
Publication Year :
2023

Abstract

Fibroblast activation protein (FAP)-radioligand therapy might be effective in some patients without being curative. FAP-radioligands deliver ionizing radiation directly to FAP <superscript>+</superscript> cancer-associated fibroblasts and, in some cancers, to FAP <superscript>+</superscript> tumor cells; in addition, they indirectly irradiate FAP <superscript>-</superscript> cells in tumor tissue via cross-fire and bystander effects. Here, we discuss the potential to improve FAP-radioligand therapy through interfering with DNA damage repair, immunotherapy, and co-targeting cancer-associated fibroblasts. As the molecular and cellular effects of FAP-radioligands on the tumor and its microenvironment have not been investigated yet, we call for future research to close this gap in knowledge, which prevents the development of more effective FAP-radioligand therapies.<br /> (Copyright © 2023 Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1879-9809
Volume :
18
Issue :
3
Database :
MEDLINE
Journal :
PET clinics
Publication Type :
Academic Journal
Accession number :
36990945
Full Text :
https://doi.org/10.1016/j.cpet.2023.02.006